Status:

COMPLETED

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

Lead Sponsor:

Korea University Guro Hospital

Conditions:

Streptococcal Pneumonia

HIV/AIDS

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optima...

Detailed Description

This single-center, open-label non-randomized clinical trial was conducted at Korea University Guro Hospital from April 2015 to January 2017. Based on the CD4 T-cell counts at the time of study enroll...

Eligibility Criteria

Inclusion

  • HIV-infeted subjects who received antiretroviral therapy for ≥ 4 weeks

Exclusion

  • a history of pneumococcal infection within the recent five years
  • previous pneumococcal vaccination
  • current opportunistic infections
  • known immunodeficiency other than HIV infection
  • coagulation disorders

Key Trial Info

Start Date :

April 2 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 28 2017

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT03838497

Start Date

April 2 2015

End Date

February 28 2017

Last Update

February 12 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults | DecenTrialz